ArticlemedRxiv : the preprint server for health sciences2024
CSF inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer's disease spectrum.
Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
7 authors.
Funding
Abstract
Background: A growing body of evidence suggests that neuroinflammation contributes actively to pathophysiology of Alzheimer's disease (AD) and promotes AD progression. The predictive value of neuroinflammatory biomarkers for disease-staging or estimating disease progression is not well understood. In this study, we investigate the diagnostic and prognostic utility of inflammatory biomarkers in combination with conventional AD biomarkers. Methods: We included 258 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who had CSF biomarkers of β-Amyloid (Aβ), tau, and inflammation. The primary outcome of interest was clinically meaningful cognitive decline (CMCD) as defined by an increase of ≥4 on the Alzheimer's Disease Assessment Scale Cognitive Subscore 11 (ADAS-11, scores 0-70, higher scores indicate worse cognition). Predictor variables were categorized as demographics (D; age, sex, and education), genetic (APOE4 status (A)), inflammatory biomarkers (I), and classic (C) cerebrospinal fluid (CSF) biomarkers of Aβ and p-tau181. Simultaneous inclusion of eleven CSF inflammatory biomarkers as covariates in logistic regression models was examined to assess improvements in classifying baseline clinical diagnoses (cognitively normal (CN), mild cognitive impairment (MCI), Dementia) and predicting individuals with and without CMCD over one year of follow-up. Results: At 1-year follow up, 27.1% of participants experienced CMCD. Inclusion of inflammatory biomarkers improved baseline classification of CN vs MCI as well as CN vs Dementia for models including D and A variables (DA; both Conclusions: Addition of CSF inflammatory biomarkers to CSF biomarkers of AD can improve diagnostic accuracy of clinical disease stage at baseline and add incremental value to AD biomarkers for prediction of cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.